PLUS1
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 5.35 ▼ -0.10 (-1.76%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.199 | 3.79% | 5.4453 | 5.55 | 5.26 | 5.35 | 5.2463 | 17:00:28 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 5.28 | 5.50 | 0.22 | 4.0% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 64 | 15,658 | $ 5.41 | $ 84,691 | 55,921 | 1.41 - 5.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:59:40 | 12 | $ 5.54 | USD |
ESSA Pharma Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 113.06M | 20.76M | $ -11.63M | -2.63 | - | 20.76M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
ESSA Pharma News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/12/2019 | 14:32 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 11/06/2019 | 06:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) |
| 11/05/2019 | 13:19 | Edgar (US Regulatory) | Securities Registration (foreign Private Issuer) (f-3/a) |
| 10/30/2019 | 09:02 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/30/2019 | 06:00 | PR Newswire (Canada) | ESSA Pharma Grants Stock Options |
| 10/28/2019 | 13:03 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/28/2019 | 07:30 | PR Newswire (Canada) | ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.75 | 5.75 | 4.80 | 5.00 | 126,233 | -0.3047 | -5.3% |
| 1 Month | 4.37 | 5.75 | 3.92 | 4.99 | 61,894 | 1.08 | 24.61% |
| 3 Months | 2.9722 | 5.75 | 2.80 | 4.37 | 43,429 | 2.47 | 83.21% |
| 6 Months | 2.2652 | 5.75 | 1.41 | 3.49 | 35,258 | 3.18 | 140.39% |
| 1 Year | 2.47 | 5.75 | 1.41 | 3.44 | 22,233 | 2.98 | 120.46% |
| 3 Years | 2.3612 | 5.83 | 0.10 | 0.9601686 | 55,047 | 3.08 | 130.62% |
| 5 Years | 8.30 | 11.69 | 0.10 | 1.07 | 42,251 | -2.85 | -34.39% |
ESSA Pharma Description
| ESSA Pharma Inc is a pharmaceutical company. The company is in preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs which selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |
